Journal September 25, 2026 7 min read

Common Misconceptions About Prolactin: A Research Perspective

Prolactin is a peptide hormone and cytokine, not a female reproductive hormone. This article examines common misconceptions about prolactin using evidence from recent studies on pituitary pathology, performance-enhancing

peptides-pro Editorial

What is prolactin?

Prolactin (PRL) is a peptide hormone and cytokine, also known as lactotropin or mammotropin. It is a member of the somatotropin/prolactin family of hormones and is encoded by the PRL gene. The mature hormone consists of 199 amino acids and has a molecular weight of approximately 23 kDa. Prolactin is produced primarily by lactotroph cells in the anterior pituitary gland, but it is also synthesized in numerous extrapituitary sites, including the decidua, myometrium, breast, lymphocytes, and prostate.

Prolactin exerts its effects by binding to the prolactin receptor (PRLR), a member of the cytokine receptor superfamily, which signals through the JAK/STAT pathway, particularly JAK2 and STAT5.

Research Studies

Prolactin and pituitary abscess in POEMS-like syndrome

A case report described a patient with a pituitary abscess and a POEMS-like syndrome, a rare co-presentation that had not been previously reported [1]. POEMS syndrome is a paraneoplastic disorder characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes, with chronic cytokine overproduction. Pituitary abscess is a life-threatening condition that can lead to panhypopituitarism. The report highlighted the diagnostic challenge posed by the overlapping clinical manifestations, which can lead to misdiagnosis or delayed treatment [1]. Prolactin levels were not specifically detailed in the available summary, but the case underscores the need to consider pituitary pathology in patients with complex endocrine and neurological symptoms.

Prolactin and pituitary metastasis: clinical red flags

A retrospective case series of 14 patients with pituitary metastasis diagnosed between 2010 and 2025 characterized the clinical presentation, endocrine phenotype, and outcomes [2]. Median age was 52.5 years. Presenting manifestations included headache, visual disturbances, and endocrine deficits. Prolactin levels were among the endocrine parameters assessed, although specific values were not provided in the summary. The study emphasized diagnostic red flags such as rapid onset of symptoms, diabetes insipidus, and cranial nerve palsies, which should prompt urgent evaluation [2].

Prolactin and performance-enhancing peptides modulating the GH-IGF1 axis

A review of performance-enhancing drugs marketed as "research compounds" discussed unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis [3]. Agents included GHRH analogues (e.g., sermorelin, tesamorelin, CJC-1295 with or without DAC), growth hormone secretagogues (e.g., GHRP-2, GHRP-6, hexarelin, ipamorelin), the GH fragment AOD9604, and IGF-1 analogues. While prolactin was not the primary focus, the review noted that some of these peptides can influence prolactin secretion, and self-administration protocols often lack monitoring for adverse endocrine effects [3].

Prolactin and the dorsal vagal complex: insights from cagrilintide

A cross-species atlas of the dorsal vagal complex (DVC) examined the effects of cagrilintide, an amylin receptor agonist, on energy balance [4]. The study generated a transcriptomics atlas of over 530,000 cells from rat, mouse, and macaque caudal brainstem. It identified two conserved Calcr-expressing DVC neuronal populations regulated by cagrilintide. While prolactin was not directly investigated, the DVC is a key site for the integration of metabolic and neuroendocrine signals, and prolactin receptors are expressed in this region. The findings suggest that prolactin may interact with DVC circuits, but this remains speculative [4].

Prolactin and asprosin in SSRI-induced male dysfunction

Asprosin, a fasting-induced adipokine, was shown to act centrally to restore erectile function, copulatory behavior, and testicular morphology in selective serotonin reuptake inhibitor (SSRI)-treated rats [5]. The study positioned asprosin as a promising therapeutic candidate for antidepressant-induced sexual dysfunction. Prolactin is known to be elevated by SSRIs and has been implicated in sexual dysfunction, but the study did not directly measure prolactin. The findings highlight the complex interplay between adipokines, neurotransmitters, and reproductive function [5].

Prolactin and secondary colostrum components in neonatal calves

A scoping review on bovine colostrum examined the effects of secondary components—cytokines, oligosaccharides, fatty acids, enzymes, and other nutrients—on neonatal calf physiology and metabolism [6]. While prolactin is a component of colostrum, the review focused on other bioactive factors. It noted that emerging evidence indicates these secondary components play critical roles in metabolism and physiological development, and that understanding their dynamics could refine colostrum management strategies [6].

Prolactin as a biomarker in cognitive studies under hypoxia

A clinical trial investigating the cognitive effects of a blackcurrant-based drink under normobaric hypoxia (4,500 m for ~180 minutes) will assess prolactin as a biomarker among other physiological measures [7]. The double-blind, randomised, placebo-controlled crossover design aims to determine if the nootropic drink can support cognitive function under simulated high-altitude conditions. Prolactin is included in the biomarker panel, but its specific role in this context is not yet defined [7].

Prolactin and cytokines in migraine pathophysiology

A clinical trial exploring the role of cytokines and regulatory T lymphocytes in migraine pathophysiology will investigate several peptides, including calcitonin gene-related peptide (CGRP) [8]. Prolactin is not explicitly mentioned in the summary, but migraine is more prevalent in women and in patients with autoimmune and inflammatory diseases, suggesting a potential hormonal link. The study aims to clarify migraine pathophysiology and identify new treatment targets [8].

Prolactin and hormone metabolism in overweight women: a probiotic trial

A randomized, double-blind, placebo-controlled trial investigated the effects of a 12-week multi-strain probiotic intervention on endocrine, metabolic, and psychological parameters in overweight women [9]. The study assessed hormone metabolism, body composition, and emotional regulation. Prolactin was among the hormones measured, although specific results were not provided in the summary. The trial aimed to address the limited robust evidence on probiotics for female obesity linked to endocrine-metabolic-gut-brain axis dysfunction [9].

Prolactin and seasonal brain plasticity in photoperiodic animals

Transcriptomic analyses of limbic structures in Siberian hamsters and Japanese quail across photoperiodic phenotypes revealed seasonal morphological brain plasticity [10]. Prolactin is a key mediator of seasonal adaptations in these species, influencing behavior and physiology. The study identified structural changes in the hippocampus and amygdala (nucleus taeniae in birds) that are thought to underlie seasonal shifts in emotional state. While the findings are animal-specific, they suggest conserved mechanisms that may have implications for human seasonal affective disorders [10].

Prolactin and hypophysitis in sarcoidosis

A systematic review characterized hypophysitis in sarcoidosis, a rare manifestation of neurosarcoidosis that can cause permanent endocrine dysfunction, visual impairment, and neurological morbidity [11]. Prolactin deficiency or excess may occur depending on the pattern of pituitary involvement. The review highlighted the need for early diagnosis and multidisciplinary management to prevent long-term complications [11].

Prolactin and GnRH agonists in premenopausal breast cancer

A retrospective cohort study compared the efficacy and safety of goserelin versus leuprolide, both GnRH agonists used for ovarian function suppression in premenopausal breast cancer patients receiving adjuvant endocrine therapy [12]. While prolactin was not the primary endpoint, GnRH agonists can indirectly affect prolactin levels through modulation of the hypothalamic-pituitary-gonadal axis. The study aimed to determine if differences in molecular structure lead to clinically meaningful differences in outcomes [12].

If you are reading this for personal health reasons

The compounds and research materials discussed here are sold for laboratory research only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.